Clinical Trials Browser

Approved for marketing × Lymphoma × Clear all

NCT05733650 2023-05-25

Expanded Access Program for Epcoritamab

Approved for marketing

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

Approved for marketing

LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency